Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study
Ioanna Minopoulou(Friedrich-Alexander-Universität Erlangen-Nürnberg), Filippo Fagni(Universitätsklinikum Erlangen), David Simón(Rush University Medical Center), Arnd Kleyer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Daniela Bohr(Friedrich-Alexander-Universität Erlangen-Nürnberg), Melek Yalçın Mutlu(Bakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi), Koray Taşçılar(Friedrich-Alexander-Universität Erlangen-Nürnberg), Giulia Corte(Friedrich-Alexander-Universität Erlangen-Nürnberg), Bernhard Manger(Universitätsklinikum Erlangen), Georg Schett(Karolinska University Hospital), Thomas Harrer(Friedrich-Alexander-Universität Erlangen-Nürnberg), F Hartmann(Universitätsklinikum Erlangen), Karin Manger(University of Bamberg), Klaus Korn(University of Bonn), Katja Schmidt(German Cancer Research Center)
Cited by 1
Related Papers
Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock
|CHEST Journal|2009|1.2k
Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin
|Journal of Clinical Investigation|2012|708
EULAR definition of difficult-to-treat rheumatoid arthritis
|Annals of the Rheumatic Diseases|2020|538
Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease
|Circulation|2004|507
Prospective Study on Circulating MicroRNAs and Risk of Myocardial Infarction
|Journal of the American College of Cardiology|2012|463